Since 15 June 2026, France’s statutory health insurance reimburses Wegovy and Mounjaro at 65 percent. Germany lists the same two products, by name, as lifestyle drugs, in the same legal category as products for hair growth and erectile dysfunction. Same continent, same molecules, opposite answer.
This article is not an argument that anyone should take these drugs, and it is not a recommendation to lose weight. Fatosphere does not do either. It is about something else: two European states looking at identical evidence and deciding, in opposite directions, whether care for fat people is medicine or a matter of personal taste. And about the fact that both systems, in different ways, make fat people justify themselves first.
What France decided
Two ministerial orders published in the French Journal officiel on 28 May 2026 added Wegovy (semaglutide) and Mounjaro (tirzepatide) to the list of reimbursable medicines. Reimbursement started on 15 June 2026 at 65 percent, meaning a patient share of 35 percent, with full coverage possible depending on individual status, long-term illness (ALD) recognition and supplementary insurance.
The conditions are narrow. The French government’s own citizen information service describes the eligible group as people who would qualify for bariatric surgery: a BMI of 40 or higher without a weight-related comorbidity, or 35 or higher with at least one. The drugs count as second-line treatment, permitted only after a documented failure of nutritional management, which the same page defines as less than 5 percent weight loss after six months. They must be prescribed alongside a hypocaloric diet and increased physical activity.
Who may prescribe is restricted too. According to the French health insurance service Assurance Maladie, the first prescription that triggers reimbursement is reserved for specialists working in obesity care: specialised obesity centres, university hospitals, certain rehabilitation and nutrition units, or endocrinologists working with such a centre. Renewals can then come from a general practitioner. An accompanying form has to be filled in once by an authorised doctor, given to the patient and handed to the pharmacist at every dispensing. People who were already buying these drugs privately before 15 June need that form as well if they want their prescriptions reimbursed.
What Germany decided
Germany did not reject reimbursement after weighing the evidence. It never got that far, because the question was settled in 2004.
Section 34 of the German Social Code, Book V, excludes from statutory coverage all medicines whose use is primarily about increasing quality of life. The statute then names its own examples. In the original German wording, the excluded categories are drugs used mainly for erectile dysfunction, for arousal and increasing sexual potency, for smoking cessation, for slimming or curbing the appetite, for regulating body weight, or for improving hair growth (our translation). Body weight sits in that list, in that sentence, next to hair.
On 21 March 2024 the Federal Joint Committee, the G-BA, formally added Wegovy to Annex II of its medicines directive, the annex headed “lifestyle drugs”. Its own press release is unusually candid about how little room it had. During the consultation the committee considered demands for an exception at least for people with a BMI above 30 and weight-related conditions, and concluded that it had no discretion to grant one. The same release notes a consequence that is easy to miss: because the exclusion attaches to the approved indication, Wegovy also cannot be included in Germany’s structured treatment programme for obesity, the DMP Adipositas, which the G-BA had just adopted. The state runs a structured disease management programme for the condition and is legally barred from putting the drug into it.
Mounjaro followed on 19 September 2024. The committee’s own note on that decision states the reasoning plainly: classification as a lifestyle drug is not defined by the disease value of the underlying indication. It follows instead from the match between the approved use, weight reduction, and the examples written into the statute. The committee cites a 2012 Federal Social Court ruling (B 6 KA 50/11 R) for the proposition that it has no discretion here, and calls its own listing merely declaratory.
Read that again, because it is the whole point. Germany’s health authority is not saying that fatness is not a medical matter. It is saying that the question does not arise. The label says weight regulation, the statute says weight regulation, and everything else, including whether the person in front of you is ill, is legally irrelevant.
One molecule, two names, two answers
Semaglutide is sold in Germany as Wegovy, Ozempic and Rybelsus. Ozempic and Rybelsus are approved for type 2 diabetes and have been reimbursable since they entered the market. Wegovy is the same active substance, approved for weight regulation, and is not reimbursable. Tirzepatide works the same way: excluded under the Mounjaro weight-regulation indication, still a statutory benefit for type 2 diabetes.
The chemistry does not change at the pharmacy counter. What changes is which sentence on the marketing authorisation the insurer reads. A body that has already developed diabetes gets treatment paid for. The same body one diagnosis earlier does not.
Both systems make you prove something first
It would be easy to read this as France good, Germany bad. It is not that simple, and the French rule deserves the same scrutiny.
To qualify in France you must first have failed. Not failed in a vague sense: the criterion is a documented course of nutritional management that produced less than 5 percent weight loss in six months. Dieting is not merely permitted alongside the drug, it is the entry ticket, and the drug is only unlocked once the diet has demonstrably not worked. The state has written the logic of diet culture into a reimbursement rule and given it a form number. Then it requires the diet to continue anyway, since the prescription is only valid alongside a hypocaloric regime and increased physical activity.
Germany’s version of prove it is shorter and blunter. There is nothing to prove, because the category has already been decided. If you want the drug you pay for it yourself, and if you cannot, that is treated as a private matter about quality of life.
Both are moral tests. One asks you to document that you tried hard enough. The other tells you the whole area is your own business. Neither starts from the question a health system is supposed to ask, which is what this particular person actually needs.
The contradiction Germany has not resolved
Germany’s own institutions do not agree with each other.
Bariatric surgery is a statutory benefit. The drug is not. That gap is exactly what the petition behind a November 2025 decision of the Bundestag’s petitions committee was about: the petitioner argued that stomach reduction surgery plus lifelong follow-up costs more than lifelong drug treatment. On 12 November 2025 the committee decided, by a broad majority, that reimbursement in cases of medical necessity was “worth considering”, and recommended forwarding the petition to the Federal Health Ministry “as material”. In its reasoning it pointed straight back at section 34 and the lifestyle category, and said conclusive long-term data on cardiovascular endpoints and drug safety should be awaited.
Worth considering and as material are the parliamentary vocabulary for nothing happening yet. Nine months later, nothing has. And because the G-BA has already stated that it has no discretion, this cannot be fixed by the committee that made the listing. Changing it means changing the statute, which is a job for the legislature, not the regulator.
Why we are writing about this at all
Fatosphere does not tell anyone to take these drugs, and we do not treat weight loss as a goal worth pursuing. Our interest in GLP-1 policy has always been the same one: what it reveals about who is allowed access to medical care, and on what terms.
Until now we could only tell that story with American material, where private insurers, Medicaid programmes and federal pilots open and close the door month by month. France and Germany let us tell it inside one continent, under two systems that both claim to cover everyone. A person with the same body, the same diagnoses and the same doctor gets a different answer depending on which side of the Rhine they live on. That is not medicine. That is administrative geography.
And the German category is worth naming for what it is. Placing body weight in a legal list with hair growth and sexual potency was a political choice made in 2004, at a time when almost none of the current evidence existed. It has since become a rule that its own enforcers say they cannot bend. Whatever you think about these drugs, and there are good reasons for scepticism about a market this loud, a health system that decides in advance that the topic is a matter of lifestyle has stopped asking the medical question. It has just made the answer someone else’s problem.
What we are watching
- Whether the Federal Health Ministry does anything with the petition it received as material in November 2025.
- Whether France’s narrow criteria hold, and who ends up excluded by the requirement to have documented a failed diet first.
- Whether other EU states follow one model or the other, which will show whether the French decision was an outlier or the beginning of a split.
Related reading
Our earlier work on the same question, from the American side: Fat and Poor: The GLP-1 Access Gap Punishes Twice. On rights in and outside the doctor’s office: When the World Isn’t Built for You: Weight Discrimination, and What to Do About It and What to Do When a Doctor Blames Everything on Your Weight.
Sources
- Service-Public.fr (Direction de l’information légale et administrative), “Deux médicaments contre l’obésité remboursés depuis le 15 juin”, published 1 June 2026, updated 15 June 2026.
- Assurance Maladie (ameli.fr), “Obésité : de nouveaux médicaments peuvent être pris en charge dans des conditions encadrées”, 16 June 2026.
- Section 34 of the German Social Code Book V (SGB V), full text at gesetze-im-internet.de.
- Gemeinsamer Bundesausschuss, press release, “G-BA vollzieht den gesetzlichen Verordnungsausschluss für das Abmagerungsmittel Wegovy nach”, 21 March 2024.
- Gemeinsamer Bundesausschuss, professional news item, “Tirzepatid und Ritlecitinib als Lifestyle-Arzneimittel gelistet”, 20 September 2024, on the decision of 19 September 2024.
- Deutscher Bundestag, hib 605/2025, “Übernahme der Kosten für die Abnehmspritze durch die GKV”, 12 November 2025, on petition ID 165851.